DYN · ISSUER CIK 1818794
Dyne Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Dyne Therapeutics, Inc. insiders reported $40K of open-market purchases and $65.7M of sales on SEC Form 4. The largest buyer was Posner Brian S (Director), with $40K.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 8 of 8 sales were reported under a 10b5-1 plan.
$40KInsider buying
$65.7MInsider selling
−$65.6MNet open-market
Oct 22, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22, 202616:10 | Oct 20, 2026 | DYN | Head of R&D and CMO | A · Grant | — | +8,000 | 170,564 | +5% | — | ||
| Oct 6, 202616:15 | Oct 2, 2026 | DYN | Director | P · Buy | $16.00 | +2,500 | 27,000 | +10% | +$40K | -40.3% | +6.5% |
| Sep 8, 202616:15 | Sep 8, 2026from Sep 4, 2026 | DYN | Chief Commercial Officer | S · Sell10b5-1 | $23.42 | −1,085 | 152,897 | -1% | −$25K | ||
| Sep 8, 202616:14 | Sep 8, 2026from Sep 4, 2026 | DYN | Chief Medical Officer | S · Sell10b5-1 | $22.95 | −5,035 | 162,564 | -3% | −$116K | ||
| Sep 8, 202616:13 | Sep 8, 2026 | DYN | CEO & President, Director | S · Sell10b5-1 | $18.88 | −5,658 | 357,507 | -2% | −$107K | ||
| Aug 17, 202617:30 | Aug 14, 2026from Aug 13, 2026 | DYN | Director | S · Sell10b5-1 | $25.20 | −2,586,928 | 428,946 | -86% | −$65.2M | ||
| Aug 17, 202616:08 | Aug 13, 2026 | DYN | Chief Commercial Officer | S · Sell10b5-1 | $26.28 | −226 | 153,982 | -0% | −$6K | ||
| Aug 17, 202616:08 | Aug 13, 2026 | DYN | Chief Medical Officer | S · Sell10b5-1 | $26.28 | −1,556 | 167,599 | -1% | −$41K | ||
| Aug 17, 202616:07 | Aug 13, 2026 | DYN | CEO & President, Director | S · Sell10b5-1 | $26.28 | −4,986 | 363,165 | -1% | −$131K | ||
| Aug 17, 202616:06 | Aug 13, 2026 | DYN | Chief Financial Officer | S · Sell10b5-1 | $26.28 | −1,797 | 119,766 | -1% | −$47K |